Immunic releases its quarterly financial results and corporate progress updates periodically in accordance with regulatory reporting schedules mandated by the U.S. Securities and Exchange Commission. Earnings announcements and conference call dates are typically scheduled at the close of each financial quarter—covering periods ending in March, June, September, and December—with exact dates published in advance on the investor relations section of the company's official website. These reports provide vital transparency regarding cash runway status, research expenditures, and clinical trial milestones.